A novel biomarker for non-alcoholic fatty liver disease has been discovered using transcriptomic analysis, paving way for non-invasive diagnostic procedures. With the rising prevalence of obesity,...
Researchers from Duke-NUS Medical School, Erasmus University Medical Center, Yale-NUS College and Duke University have found a potential way to predict who will respond to cancer therapies. Wnt...
Data from collaborative study between MiRXES and Janssen demonstrate how miRNA-based biomarker signatures could lead to potential in early identification and diagnosis of pulmonary hypertension....
Researchers from the National Cancer Centre Singapore (NCCS) discover a genetic marker that identifies patients of aggressive blood cancer likely to respond well to a novel immunotherapy treatment...
Fluidigm and the Singapore Immunology Network (SIgN), establish the first center of excellence in Singapore and Southeast Asia for advancement in highly multiplexed tissue imaging in translational...
Local Singapore-based biotech company, MiRXES Pte Ltd, spun off from the Agency for Science, Technology and Research (A*STAR) in Singapore in 2014. Their microRNA research and technology platform...
Understanding the activation of TNAP gene by HLA-B27 in the pathogenesis of Ankylosing Spondylitis (AS) for development of diagnosis strategies. In a collaborative research led by Dr. Lin Kuo-I of...
In the Asia Pacific region, precision medicine in cancer treatment has come a long way, but according to Vishal Doshi, CEO of AUM Biosciences, we still have work to do in ensuring that we translate...
